Immucor Up 6.1% On Earnings Report (BLUD)

Shares of Immucor, Inc. BLUD are trading up 6.1% at $20.48 per share during the Friday afternoon trading session. After the market closed on Thursday, the company reported 2nd quarter earnings of 30 cents per share, on revenue of $81.5 million. President and chief executive officer Gioacchino De Chirico said, "On the whole, our second quarter performance was in line with our expectations. We continue to see weakness in the U.S. market due to the macroeconomic environment, which is impacting both our reagent revenue and instrument orders." The day's range for shares of Immucor, Inc has been between $20.15 and $21.00 per share. The average price target of analysts who cover Immucor, Inc. (BLUD) is $20.13 per share. Volume of 746,000 shares is already approaching the daily average volume of 807,000 shares. Immucor, Inc manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Read more from Benzinga's Company news.